In a press release on Mar. 21, 2011, the EMA Management Board gave its approval for the current activities of former executive director Thomas Lönngren.
In a press release on Mar. 21, 2011, the EMA Management Board gave its approval for the current activities of former executive director Thomas Lönngren.
Lönngren, who stepped down on Dec. 31, 2010, came under fire from several organisations that claimed that his move to a new position as an advisor to the private pharmaceutical sector might have breached conflict-of-interest rules. In particular, the groups' letter, dated Feb. 25, 2010, expressed concern that “there was no ‘cooling off’ period between his former and current employment."
Though the EMA Management Board approved Lönngren’s recent appointments, it was quick to state that it took the agency’s role in protecting the public interest and maintaining a good reputation seriously.
The board based its decision on two factors: “Firstly, whether any activity risked the misuse of confidential or privileged information gained during his leadership of the Agency and secondly whether any activity risked improper influence on decisions taken by the Agency.” The board concluded that no risk was posed, but expressed regret at Lönngren's tardiness in notifying it of his new appointments.
Despite the approval, the board imposed a set of limitations that will remain in place for a period of two years effective immediately. The limitations forbid Lönngren to take the following actions:
By making its decision and supporting documents public, the EMA hopes to ensure accountability and allay the concerns that five European public-health and transparency campaigners raised.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.